[Current status of anticoagulants]

Area of Science:

• Pharmacology and Therapeutics
• Hematology
• Cardiovascular Medicine

Background:

• Direct thrombin inhibitors, like hirudin, target thrombin's active and recognition sites, inactivating fibrin-bound thrombin.
• Low-molecular-weight heparins (LMWH) represent an alternative therapeutic strategy in anticoagulation.

Purpose of the Study:

• To outline authorized indications and treatment recommendations for direct thrombin inhibitors and LMWH in France.
• To discuss the controversial duration of anticoagulation therapy for venous thromboembolism.
• To consider the role of oral anticoagulation in primary prevention of ischemic heart disease.

Main Methods:

• Review of authorized indications for direct thrombin inhibitors (desirudin, lepirudin) and LMWH (nadroparin, tinzaparin).
• Discussion of treatment guidelines for heparin-induced thrombocytopenia and deep venous thrombosis.
• Exploration of current recommendations regarding anticoagulation duration and primary prevention strategies.

Main Results:

• Desirudin is authorized for preventing thromboembolic complications in hip or knee replacement surgery.
• Lepirudin is recommended for heparin-induced thrombocytopenia with thrombosis; danaparoid sodium for prophylaxis.
• Nadroparin and tinzaparin are effective for treating deep venous thrombosis with once-daily dosing.

Conclusions:

• Direct thrombin inhibitors and LMWH provide effective therapeutic options for various thromboembolic conditions.
• Anticoagulation duration for venous thromboembolism should be individualized based on risk factors.
• Low-intensity oral anticoagulation may be beneficial for high-risk men in primary prevention of ischemic heart disease.